Klarissa Jackson Lab
Klarissa Jackson Lab
The Jackson laboratory utilizes human-relevant in vitro systems (hepatic cell cultures, tissue fractions, and recombinant enzymes) and liquid chromatography – mass spectrometry to study drug metabolism and disposition and address fundamental questions regarding the molecular mechanisms of drug toxicity and inter-individual variability in drug disposition. We also collaborate with basic scientists and clinical investigators to develop innovative solutions that will have a broader impact on improving drug safety and precision dosing in various therapeutic areas.
The Jackson laboratory focuses on translational research in drug metabolism and toxicology to elucidate the mechanisms of and risk factors for adverse drug reactions. An important goal of the laboratory is to identify the genetic and environmental factors that contribute to inter-individual variability in drug disposition, drug response, and drug toxicity. Our laboratory is currently investigating the influence of individual variations in cytochrome P450 and UDP-glucuronosyltransferase enzymes on the metabolism and hepatotoxicity of tyrosine kinase inhibitors used in cancer therapy as well as the natural product cannabidiol used in epilepsy treatment. We are also engaged in collaborative research to evaluate the structure-metabolism-toxicity relationships of novel compounds in drug discovery. The long-term goals of this research are to improve the prediction of serious adverse reactions, mitigate drug toxicity, and accurately tailor drug therapy in diverse patient populations.Current research projects in the Jackson laboratory include the following:
Structure-metabolism-toxicity evaluation of bioactive molecules in drug discovery (NIH/NIGMS R01 GM127774)
- Structure-metabolism-toxicity evaluation of bioactive molecules in drug discovery (NIH/NIGMS R01 GM127774)
- Metabolism and hepatotoxicity of cannabidiol
- Phenotypic biomarkers of cytochrome P450 3A for precision dosing (NC TraCS Pilot Grant 550KR231911